Today's Trend
XOMA Royalty Corporation (XOMA) — Shares rose sharply after news that Ligand Pharmaceuticals agreed to buy XOMA for $39.00 per share (deal value ~ $739M), but the stock has pulled back since that initial jump. Volume was well above average around the takeover announcement, and market pricing currently sits above the cash offer, implying the market is attributing value to contingent rights, potential competing bids, or other upside.
- Ligand announced a definitive agreement to acquire XOMA for $39.00/share in an all‑cash transaction (~$739M), which expands Ligand’s royalty portfolio and is expected to be accretive to Ligand’s EPS. Ligand to Acquire XOMA Royalty
- Insider activity and institutional flows show support: CEO Owen Hughes recently purchased 100,000 shares and several large funds increased positions, signaling insider and institutional conviction around the deal/valuation. $XOMA stock is up 9% today
- Trading was halted briefly ahead of the announcement and the name has seen elevated volume as the market reprices the company around the transaction and any attached contingent value rights. Xoma Royalty Shares Edge Up Premarket
- Multiple shareholder‑rights law firms have launched investigations into whether XOMA’s board secured a fair price, creating legal/transactional uncertainty that could delay closing or alter outcomes for shareholders. ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of XOMA Royalty Corporation
- Analyst/firm reactions are mixed: Lucid Capital Markets downgraded XOMA from “strong‑buy” to “hold,” and a Zacks note flagged that recent upward moves occurred on heavy volume but that earnings‑estimate revision trends don’t clearly support sustained strength. XOMA Royalty (XOMA) Moves 10.7% Higher
Investor takeaway: the Ligand bid establishes a clear cash floor at $39.00/share, but legal reviews, a price still trading above the offer, CVR mechanics and analyst price targets (median above the deal) create both upside scenarios and execution risk. Watch regulatory/board developments, any competing bids, CVR terms, and the company’s proxy/timing updates for news that will move the stock next.